

# ONCOLOGY AND BIOMARKERS SUMMIT

November 27-28, 2017 | Atlanta, USA

## Optimizing next-generation sequencing (NGS) and biomarkers in cancer clinical trials in Asia

Allen Lai

ACT Genomics, Singapore

Coupled with the availability of molecular therapeutic targeting genomically defined population, next-generation sequencing (NGS) based multiplexed genomic profiling has created a growing interest among cancer specialists and pharmaceutical companies. Among all, using the adequate technology platform to identify the right genomic biomarker and provide treatment options is pivotal in drug discovery and development, as well as clinical trial design. There is little doubt that the interest has been prompted by

advances in the use of biomarkers, improvements in NGS platforms and accumulating paradigms of benefit. There is much opportunity to pioneer the development of precision oncology. In this talk, the author will walk the audience through the evolution of cancer precision medicine in the search of biomarkers, and the impact to cancer clinical trials in Asia, as well as business growth potential.

e: [allenlai@actgenomics.com](mailto:allenlai@actgenomics.com)